Dazodalibep
Horizon Therapeutics
['dazodalibep', '$hznp']
presentations at the 2023 eular european congress of rheumatology highlight new results from phase 2 trial evaluating dazodalibep in sj gren s syndrome - health stocks hub $hznp 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2